
ABSTRACT Whole‐genome sequencing (WGS) and RNA sequencing (RNA‐seq) can be applied to formalin‐fixed paraffin‐embedded (FFPE) specimens for genomic and transcriptomic analyses, including gene rearrangement detection. We tested whether PCR‐free WGS and RNA‐seq could detect driver alterations in FFPE lung adenocarcinoma samples prepared under standardized automated fixation and embedding conditions. Two adenocarcinoma cases were analyzed. Before this study, immunohistochemistry had suggested an EGFR alteration in one case and an ALK alteration in the other, although neither had been confirmed at the genomic or chromosomal level. In this analysis, PCR‐free WGS yielded stable sequencing metrics and successfully detected small variants, including the canonical EGFR p.Leu858Arg mutation. By contrast, conventional structural variant calling failed to identify the EML4 :: ALK rearrangement. However, a custom algorithm based on supplementary alignment tags recovered the fusion candidate from WGS data despite support from only a single junction read, and RNA‐seq independently confirmed expression of the EML4::ALK fusion transcript. Break‐apart fluorescence in situ hybridization demonstrated tumor‐wide clonal ALK rearrangement. These findings show that a single junction read can be biologically meaningful only when supported by orthogonal pathological validation and highlight the importance of integrating sequencing findings with pathological validation for the interpretation of gene rearrangements in FFPE specimens.
ABSTRACT Accurate risk stratification for lymph node metastasis (LNM) is needed after endoscopic resection of early‐stage colorectal cancer (CRC). We explored the associations of cancer‐associated fibroblast (CAF)‐related markers and insulin‐like growth factor 2 mRNA‐binding protein 3 (IMP3) expression with LNM. We analyzed data from 155 patients with pT1 CRC who were treated by primary or additional surgery after endoscopic resection. A matched case‐control cohort comprising 18 patients with LNM and 29 LNM‐negative controls was immunohistochemically analyzed. The area fraction and staining intensity of podoplanin (D2‐40), hydrogen peroxide‐inducible clone‐5 (Hic‐5), α‐smooth muscle actin (αSMA), and IMP3 were assessed using image analysis. We evaluated CAF‐related stromal markers in the superficial, middle, and invasive front regions and IMP3 in tumor areas. Decreased D2‐40 expression at the invasive front showed a nominal association with LNM. Associations between LNM and each of Hic‐5, αSMA, and IMP3 were not statistically significant. These hypothesis‐generating findings suggest an association between reduced invasive‐front D2‐40 expression and LNM in pT1 CRC.
ABSTRACT Oral squamous cell carcinoma (OSCC) has a poor prognosis and is frequently diagnosed at advanced stages. Therefore, the identification of clinically useful tumor biomarkers is a critical unmet need. The tRNA methyltransferase subunit 11‐2 (TRMT112) forms a complex with methyltransferase‐like protein 5 (METTL5) and is involved in RNA methylation; however, limited evidence suggests a role for TRMT112 as a tumor‐promoting factor in cancer. Therefore, the biological function of TRMT112 in cancer, including OSCC, remains largely unknown, prompting this study. Analyses of public databases revealed that TRMT112 expression was associated with poor prognosis in head and neck squamous cell carcinoma and was positively correlated with METTL5 expression levels. TRMT112 was also associated with increased sensitivity to osimertinib and lestaurtinib. Furthermore, RNA polymerase II subunit G ( POLR2G ) and Sjögren's syndrome/scleroderma autoantigen 1 ( SSSCA1 , also termed ZNRD2 ) were identified as newly related genes. Immunohistochemical staining revealed that the TRMT112 protein was associated with an invasive growth pattern ( p = 0.0234) and poorer prognosis ( p = 0.0205). Functional assays indicated that TRMT112 was associated with increased invasive potential and regulation of METTL5 expression in OSCC cells. These findings suggest that TRMT112 may serve as a potential diagnostic and therapeutic target in OSCC.
Genetic tests for lung cancer, such as the Oncomine Dx Target Test (ODxTT), are essential for patient management, and require RNA and DNA of sufficient quality and quantity from formalin-fixed paraffin-embedded (FFPE) samples. ODxTT fails due to poor nucleic acid preservation. Although enhancing the penetration of formalin into tissues improves nucleic acid preservation, the clinical utility of negative-pressure fixation methods remains unclear. Therefore, we investigated whether the negative-pressure fixation method using a vacuum fixation device improves ODxTT success rates and the quality of nucleic acids in FFPE samples from lung and other cancers, and examined the underlying mechanisms. The ODxTT success rate was higher with the negative-pressure fixation method than with the conventional method (96.5% vs. 81.2%), accompanied by increased RNA quality and yield; however, no marked differences were observed in DNA. RNA deteriorated more rapidly than DNA in resected mouse liver tissues, indicating that RNA is more labile than DNA during cold ischemia. Furthermore, in FFPE samples from colon, pancreatic, and prostate cancers, negative-pressure fixation consistently improved RNA DV200. These results indicate that the negative-pressure fixation method improves ODxTT success by accelerating formalin penetration, which may suppress RNase-mediated RNA degradation and preserve RNA quality.
ABSTRACT This study clarifies the distinct clinicopathological and molecular features of amphicrine pancreatic carcinoma (AmpCA) through a case analysis and literature review. We present a case of AmpCA in a 73‐year‐old female, characterized by co‐expression of acinar cell markers and neuroendocrine markers within individual tumor cells. Molecular profiling revealed high‐risk mutations in KRAS G12V, TP53 , and RB1 , along with a high Ki‐67 index (85%). Literature comparison confirms that AmpCA exhibits a unique bidirectional, single‐cell differentiation pattern, fundamentally distinguishing it from the bicellular composition of mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNEN). We conclude that AmpCA is a distinct malignant entity requiring specific diagnostic criteria, and its molecular profile suggests potential for targeted therapies.